Boryung Pharmaceutical's BR-6002 Advances in Cardiovascular Disease Treatment

Key Insights

• Boryung Pharmaceutical is developing BR-6002, an orally administered drug, for cardiovascular diseases, as well as gastric and duodenal ulcers.
• BR-6002's development leverages GlobalData's predictive analytics for assessing the likelihood of approval based on historical drug development data.
• Boryung Pharmaceutical focuses on chronic diseases, including hypertension, dyslipidemia, diabetes, CNS disorders, and cancers, with BR-6002 potentially expanding their cardiovascular portfolio.

Boryung Pharmaceutical is advancing the development of BR-6002, an orally administered drug, targeting cardiovascular diseases, gastric ulcers, and duodenal ulcers. The drug's progress is being monitored using GlobalData's predictive analytics to assess its likelihood of approval.

Boryung Pharmaceutical, headquartered in Seoul, South Korea, focuses on manufacturing and distributing pharmaceutical products for chronic diseases. Their portfolio includes treatments for hypertension, dyslipidemia, diabetes, CNS disorders, and cancers. BR-6002 could potentially expand their offerings in the cardiovascular space.

GlobalData's Likelihood of Approval (LoA) analytics tool assesses the probability of a drug's success in clinical development and eventual approval. This tool uses machine learning and a proprietary algorithm to process data from GlobalData’s Pharmaceutical Intelligence Center, providing insights into drug-specific phase transition and LoA scores.